The epidemiology and the clinical implication of human parvovirus 4 (PARV4) in human populations is still under evaluation. The distribution of PARV4 DNA was determined in cohorts of French hemodialysis and lung transplant patients. Plasma samples (n=289) were tested for PARV4 by real-time PCR assay (ORF2), and amplification products selected at random were sequenced. Analysis of available serological and biological markers was also undertaken. Fifty-seven samples out of 185 (30.8%) were positive for PARV4 DNA in the cohort of hemodialysis patients. A higher prevalence of the virus was identified in patients with markers of HBV infection. PARV4 was also identified in 14 out of 104 samples (13.5%) from lung transplant recipients, with no clear-cut association with available clinical markers. Point mutations located on the zone of real-time detection were identified for some amplification products. This study describes the detection of PARV4 in the blood of hemodialysis and lung transplanted patients with significant difference in prevalence in these two cohorts. Further studies will be needed in order to understand better both the potential implication in host health and the natural history of this virus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.22003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the clinicopathological characteristics of children with anti-neutrophil cytoplasmic antibody-associated vasculitis with/without infection at diagnosis.
BMC Nephrol
January 2025
Department of Nephrology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.
Background: Infectious episodes contribute to morbidity and mortality in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Renal involvement, also known as ANCA-associated glomerulonephritis (AGN), is frequently observed in AAV. Little is known about whether co-infection at initial diagnosis is associated with renal outcome and prognosis in children with AGN.
View Article and Find Full Text PDFEffectiveness of complement inhibitors against refractory antibody-mediated rejection of lung transplantation: Two clinical cases.
Transpl Immunol
January 2025
Univ. Grenoble Alpes, CNRS, Pharmacy Department, TIMC, UMR5525, Grenoble Alpes University, Grenoble, France.
Antibody-mediated rejection (AMR) has been recognized as a significant cause of acute and chronic lung allograft dysfunction after lung transplantation. Some treatments, eculizumab, an anti-complement (C)5 component monoclonal antibody (Mab), seem to have a promising effect in the management of some patients with AMR. We present two patients with acute AMR after lung transplantation who received the anti-C5 Mab therapy.
View Article and Find Full Text PDFCancer Incidence and Mortality Patterns in Hemodialysis Patients: A Descriptive Study.
Cureus
November 2024
Nephrology, Nazareth Hospital Edinburgh Medical Missionary Society (EMMS), Nazareth, ISR.
Background End-stage renal disease (ESRD) is a condition where the kidneys cease functioning, requiring renal replacement therapy such as dialysis. ESRD patients face numerous health challenges, including an elevated risk of developing malignancies. Factors contributing to this increased cancer risk include immune suppression, chronic inflammation, DNA repair deficiencies, and chronic viral infections.
View Article and Find Full Text PDFExtracorporeal membrane oxygenation vs cardiopulmonary bypass in lung transplantation: an updated meta-analysis.
Gen Thorac Cardiovasc Surg
December 2024
Department of Thoracic Surgery, University of Alberta, Edmonton, Canada.
Article Synopsis
- The meta-analysis compared the outcomes of extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass (CPB) in lung transplantation across 14 studies with 1797 patients.
- ECMO was found to significantly reduce complications such as hepatic dysfunction, severe graft rejection, one-year mortality, and hospital stays, while causing longer total ischemic times.
- The study concludes that while ECMO has perioperative benefits over CPB, further investigation is needed to understand its long-term impacts due to the associated ischemic time.
Modern tools for optimizing fluid management in dialysis patients: a comprehensive review.
BMC Nephrol
December 2024
Department of Critical Care Medicine, Cooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Maintaining optimal fluid balance is crucial for patients with end-stage renal disease on dialysis, as both fluid overload and excess removal can lead to poor outcomes. Traditional approaches such as physical exam and chest X-ray have limitations when assessing volume status. This review carefully examines the tools that provide more precise options, including lung ultrasound, echocardiography, Venous Excess Ultrasound (VEXUS), bioimpedance analysis (BIA), and passive leg raise (PLR).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!